Over 60% of patients experience relapse, often due to antigen escape—a phenomenon in which tumor cells lose or alter the expression of the target antigen (CD19)—thereby diminishing the efficacy of CAR T-cell therapy and contributing to disease recurrence (5, 9, 10). Here, CD19 is linked to neoplasm.